Upcoming event

ENZAMET trial by Prof. Sweeney and Prof. Davis

Prof. Sweeney and Prof. Davis on overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.